Literature DB >> 15878878

Mechanisms of cytoplasmic {beta}-catenin accumulation and its involvement in tumorigenic activities mediated by oncogenic splicing variant of the receptor originated from Nantes tyrosine kinase.

Xiang-Ming Xu1, Yong-Qing Zhou, Ming-Hai Wang.   

Abstract

The beta-catenin pathway plays a critical role in the pathogenesis of certain types of cancers. To gain insight into mechanisms by which altered receptor tyrosine kinases regulate cytoplasmic beta-catenin accumulation, the effect of an oncogenic receptor originated from Nantes (RON) variant on beta-catenin accumulation and the role of beta-catenin in RON-mediated tumorigenic activities were studied. In NIH3T3 cells harboring oncogenic variant RONDelta160, increased beta-catenin accumulation with tyrosine phosphorylation and nuclear translocation was observed. Overexpression of RONDelta160 also resulted in increased expression of beta-catenin target genes c-myc and cyclin D1. By analyzing cellular proteins that regulate beta-catenin stabilities, it was found that RONDelta160 activates the protein disheveled (DVL) and inactivates glycogen synthase kinase-3beta by Ser-9 residue phosphorylation. These effects were channeled by RONDelta160-activated PI 3-kinase-AKT pathways that are sensitive to specific inhibitors, such as wortmannin, but not to other chemical inhibitors. Silencing RONDelta160 expression by specific small interfering RNA blocked not only beta-catenin expression but also c-myc and cyclin D1 expression, suggesting that RON expression is required for the activation of the beta-catenin signaling pathway. Moreover, it was found that knockdown of the beta-catenin gene expression by small interfering RNA techniques reduces significantly the RONDelta160-mediated NIH3T3 cell proliferation, focus-forming activities and anchorage-independent growth. Thus, the oncogenic RON variant regulates beta-catenin stabilities through activation of DVL and inactivation of glycogen synthase kinase-3beta. The activated beta-catenin cascade is one of the pathways involved in tumorigenic activities mediated by the oncogenic RON variant.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15878878     DOI: 10.1074/jbc.M414699200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  17 in total

1.  Ron receptor overexpression in the murine prostate induces prostate intraepithelial neoplasia.

Authors:  Jerilyn K Gray; Andrew M Paluch; William D Stuart; Susan E Waltz
Journal:  Cancer Lett       Date:  2011-09-24       Impact factor: 8.679

Review 2.  Function of alternative splicing.

Authors:  Olga Kelemen; Paolo Convertini; Zhaiyi Zhang; Yuan Wen; Manli Shen; Marina Falaleeva; Stefan Stamm
Journal:  Gene       Date:  2012-08-15       Impact factor: 3.688

Review 3.  MSP-RON signalling in cancer: pathogenesis and therapeutic potential.

Authors:  Hang-Ping Yao; Yong-Qing Zhou; Ruiwen Zhang; Ming-Hai Wang
Journal:  Nat Rev Cancer       Date:  2013-07       Impact factor: 60.716

Review 4.  Roles and mechanisms of alternative splicing in cancer - implications for care.

Authors:  Sophie C Bonnal; Irene López-Oreja; Juan Valcárcel
Journal:  Nat Rev Clin Oncol       Date:  2020-04-17       Impact factor: 66.675

5.  Recepteur d'Origine nantais (RON) tyrosine kinase splicing variants lacking exons 18 and 19 occur ubiquitously in lung cancer.

Authors:  Soundararajan Krishnaswamy; Abdul Khader Mohammed; Osama E Amer; Gyanendra Tripathi; Majed S Alokail; Nasser M Al-Daghri
Journal:  Int J Clin Exp Med       Date:  2015-11-15

6.  The RON receptor tyrosine kinase is a potential therapeutic target in Burkitt lymphoma.

Authors:  Xiangmin Tong; Xuewu Zhang; Jian Fan; Yin Tong; Shuangshuang Li; Jie Jin; Hangping Yao
Journal:  Cancer Biol Ther       Date:  2013-01-29       Impact factor: 4.742

7.  Ribosomal protein S6 kinase (RSK)-2 as a central effector molecule in RON receptor tyrosine kinase mediated epithelial to mesenchymal transition induced by macrophage-stimulating protein.

Authors:  Qi Ma; Sunny Guin; Snehal S Padhye; Yong-Qing Zhou; Rui-Wen Zhang; Ming-Hai Wang
Journal:  Mol Cancer       Date:  2011-05-28       Impact factor: 27.401

8.  Vitamin D3-dependent VDR signaling delays ron-mediated breast tumorigenesis through suppression of β-catenin activity.

Authors:  Abby L Johnson; Glendon M Zinser; Susan E Waltz
Journal:  Oncotarget       Date:  2015-06-30

9.  Alternative splicing and tumor progression.

Authors:  Claudia Ghigna; Cristina Valacca; Giuseppe Biamonti
Journal:  Curr Genomics       Date:  2008-12       Impact factor: 2.236

10.  Significance of the entire C-terminus in biological activities mediated by the RON receptor tyrosine kinase and its oncogenic variant RON160.

Authors:  Yi Lu; Hang-Ping Yao; Ming-Hai Wang
Journal:  J Exp Clin Cancer Res       Date:  2008-10-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.